Zoloft efficacy

By: Light_Ray Date: 23-Feb-2019
Sertraline - The Drug Classroom

Sertraline - The Drug Classroom

The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2). Overall, these studies demonstrated ZOLOFT to be superior to placebo on the Hamilton Rating Scale for Depression (HAMD-17) and the Clinical Global Impression Severity (CGI-S) of Illness and Global Improvement (CGI-I) scores. Study MDD-2 was not readily interpretable regarding a dose response relationship for effectiveness. A third study (Study MDD-3) involved adult outpatients meeting the DSM-III criteria for MDD who had responded by the end of an initial 8-week open treatment phase on ZOLOFT 50–200 mg/day. These patients (n=295) were randomized to continuation on double-blind ZOLOFT 50–200 mg/day or placebo for 44 weeks. A statistically significantly lower relapse rate was observed for patients taking ZOLOFT compared to those on placebo: ZOLOFT [n=11 (8%)] and placebo [n=31 (39%)]. Analyses for gender effects on outcome did not suggest any differential responsiveness on the basis of sex. The effectiveness of ZOLOFT in the treatment of OCD was demonstrated in three multicenter placebo-controlled studies of adult (age 18–65) non-depressed outpatients (Studies OCD-1, OCD-2, and OCD-3). All antidepressant drugs are not created equal, according to the authors of one of the few studies that have ever systematically analyzed and compared "new generation" medicines for treating depression. In the analysis of 12 drugs, two came out on top as the most effective and best tolerated as first-line treatments: sertraline (Zoloft) and escitalopram (Lexapro). Venlafaxine (Effexor) and mirtazapine (Remeron) rounded out the top four for effectiveness, but venlafaxine was also among the four drugs patients were most likely to quit taking because of side effects. H., who coauthored a review of the benefits and risks of the same 12 drugs published last November in the Annals of Internal Medicine. Reboxetine (Edronax) was less effective than the rest. Parikh, who wrote a comment accompanying the study that is published in the current issue of The Lancet, says the findings have "enormous implications" because, for the first time, they offer doctors an evidence-based, unbiased way to recommend treatment. He and his colleagues concluded, based on their review done while Gartlehner was at the RTI-UNC Evidence-Based Practice Center in Chapel Hill, North Carolina., that there was no clinically meaningful evidence that any one of the drugs was better than the rest. While psychiatrists treating depressed patients every day have had a sense of which medications are best, the current study "nails it," says Sagar V. And, he adds, they give patients a "gold standard of reliable information," especially since the study's authors plan to make their findings available free on the Web. Instead, they argued, decisions on which drug to use should be based on factors such as cost and side effects. D., of the University of Verona in Italy, and colleagues used a new technique called multiple-treatments meta-analysis to make head-to-head comparisons among the 12 drugs, incorporating 117 randomized controlled trials including 25,928 patients in all. There has been little scientific evidence of the relative effectiveness of these drugs, because most studies compare one against a handful of others or a placebo, and are often funded by the maker of a particular drug, which can bias the findings in its favor, the researchers note. Health.com: How to brighten your winter mood They used two measurements to gauge a drug's effectiveness and tolerability: the percentage of patients who showed at least a 50 percent improvement in their symptoms as measured by one of two scales, or who scored "much improved or very much improved" after eight weeks of treatment (or from six to twelve weeks if eight-week data weren't available) and the percentage of patients who dropped out of the study before eight weeks for any reason.

Sertraline <b>efficacy</b> - MedHelp

Sertraline efficacy - MedHelp

We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our Advertising Policy and Privacy Policy. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States. Sertraline is used for a number of conditions, including major depressive disorder (MDD), obsessive–compulsive disorder (OCD), body dysmorphic disorder (BDD), posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder, and social anxiety disorder (SAD). The comparative efficacy of sertraline and TCAs for melancholic depression has not been studied. A 1998 review suggested that, due to its pharmacology, sertraline may be more efficacious than other SSRIs and equal to TCAs for the treatment of melancholic depression. A meta-analysis of 12 new-generation antidepressants showed that sertraline and escitalopram are the best in terms of efficacy and acceptability in the acute-phase treatment of adults with unipolar MDD. Sertraline used for the treatment of depression in elderly (older than 60) patients was superior to placebo and comparable to another SSRI fluoxetine, and TCAs amitriptyline, nortriptyline (Pamelor) and imipramine. Sertraline had much lower rates of adverse effects than these TCAs, with the exception of nausea, which occurred more frequently with sertraline. In addition, sertraline appeared to be more effective than fluoxetine or nortriptyline in the older-than-70 subgroup. placebo in elderly patients showed a statistically significant (that is, unlikely to occur by chance), but clinically very modest improvement in depression and no improvement in quality of life. A meta-analysis on SSRIs and SNRIs that look at partial response (defined as at least a 50% reduction in depression score from baseline) found that sertraline, paroxetine and duloxetine were better than placebo.

<b>Efficacy</b> of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder

Objective Sertraline's efficacy and toler- ability in treating generalized anxiety dis- order were evaluated. Method Adult outpatients with DSM-IV generalized. Feb 1, 2013. Most of the Zoloft clinical trials that focused on its efficacy proved to be either negative or neutral. In most of the efficacy studies, Zoloft was not.

Zoloft efficacy
Rating 4,3 stars - 885 reviews